Screener
iRadimed IRMD R&D
R&D at other companies
Other financials
Where this comes from
Reported directly by iRadimed in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: iRadimed’s 10-Q, filed May 1, 2026.
- Filed
- May 1, 2026, 4:08 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-029325
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| General and administrative | 4,569 | 4,611 |
| Sales and marketing | 4,052 | 4,176 |
| Research and development | 956 | 624 |
| Total operating expenses | 9,577 | 9,411 |
| Income from operations | 7,237 | 5,432 |
| Other income, net | 532 | 513 |
| Income before provision for income taxes | 7,769 | 5,945 |
Item 1. Condensed Financial Statements
FAQ
- What is iRadimed's R&D?
- iRadimed (IRMD) reported R&D of $956K in Q1 2026.
- How has iRadimed's R&D changed year-over-year?
- iRadimed's R&D increased by 53.2% year-over-year, from $624K to $956K.
- What is the long-term trend for iRadimed's R&D?
- Over 4 years (2021 to 2025), iRadimed's R&D has grown at a 11.8% compound annual growth rate (CAGR), from $1.91M to $2.97M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about iRadimed's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude